Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruno Stankoff

Showing results (141-150 of 160) with videos related to

Pageof 16
Sort By:
Neurology|December 23, 2022
Investigating the Long-term Effect of Pregnancy on the Course of Multiple Sclerosis Using Causal InferenceAntoine Gavoille, Fabien Rollot, Romain Casey, et al.
Neurology|July 16, 2025
Use of Disease-Modifying Therapies in Patients With Late-Onset Multiple SclerosisCamille Robin, Fabien Rollot, Mathilde Lefort, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|September 4, 2025
Target trial emulation to replicate randomised clinical trials using registry data in multiple sclerosisAntoine Gavoille, Mikail Nourredine, Fabien Rollot, et al.
European Journal of Neurology|May 2, 2025
Secondary progression activity monitoring in MS despite an early highly active treatment the SPAM studyMikael Cohen, Fabien Rollot, Marc Debouverie, et al.
JAMA Neurology|July 1, 2024
Acute Clinical Events Identified as Relapses With Stable Magnetic Resonance Imaging in Multiple SclerosisAntoine Gavoille, Fabien Rollot, Romain Casey, et al.
JAMA Neurology|March 25, 2024
High-Efficacy Therapy Discontinuation vs Continuation in Patients 50 Years and Older With Nonactive MSGuillaume Jouvenot, Guilhem Courbon, Mathilde Lefort, et al.
Neurology|May 5, 2026
Differences in Use of Disease-Modifying Therapies Between Patients With Late-Onset and Adult-Onset Relapsing-Remitting Multiple SclerosisAntoine Gavoille, Anne Kerbrat, Gilles Edan, et al.
Brain : a Journal of Neurology|December 21, 2024
De-escalating and discontinuing disease-modifying therapies in multiple sclerosisGéraldine Androdias, Jan D Lünemann, Elisabeth Maillart, et al.
Annals of Neurology|May 23, 2024
Grey Matter Atrophy and its Relationship with White Matter Lesions in Patients with Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease, Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder, and Multiple SclerosisRosa Cortese, Marco Battaglini, Ferran Prados, et al.
Brain : a Journal of Neurology|December 14, 2022
Clinical and MRI measures to identify non-acute MOG-antibody disease in adultsRosa Cortese, Marco Battaglini, Ferran Prados, et al.
Pageof 16

Showing results (141-150 of 160) with videos related to

Sort By:
Pageof 16
Neurology|December 23, 2022
Investigating the Long-term Effect of Pregnancy on the Course of Multiple Sclerosis Using Causal InferenceAntoine Gavoille, Fabien Rollot, Romain Casey, et al.
Neurology|July 16, 2025
Use of Disease-Modifying Therapies in Patients With Late-Onset Multiple SclerosisCamille Robin, Fabien Rollot, Mathilde Lefort, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|September 4, 2025
Target trial emulation to replicate randomised clinical trials using registry data in multiple sclerosisAntoine Gavoille, Mikail Nourredine, Fabien Rollot, et al.
European Journal of Neurology|May 2, 2025
Secondary progression activity monitoring in MS despite an early highly active treatment the SPAM studyMikael Cohen, Fabien Rollot, Marc Debouverie, et al.
JAMA Neurology|July 1, 2024
Acute Clinical Events Identified as Relapses With Stable Magnetic Resonance Imaging in Multiple SclerosisAntoine Gavoille, Fabien Rollot, Romain Casey, et al.
JAMA Neurology|March 25, 2024
High-Efficacy Therapy Discontinuation vs Continuation in Patients 50 Years and Older With Nonactive MSGuillaume Jouvenot, Guilhem Courbon, Mathilde Lefort, et al.
Neurology|May 5, 2026
Differences in Use of Disease-Modifying Therapies Between Patients With Late-Onset and Adult-Onset Relapsing-Remitting Multiple SclerosisAntoine Gavoille, Anne Kerbrat, Gilles Edan, et al.
Brain : a Journal of Neurology|December 21, 2024
De-escalating and discontinuing disease-modifying therapies in multiple sclerosisGéraldine Androdias, Jan D Lünemann, Elisabeth Maillart, et al.
Annals of Neurology|May 23, 2024
Grey Matter Atrophy and its Relationship with White Matter Lesions in Patients with Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease, Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder, and Multiple SclerosisRosa Cortese, Marco Battaglini, Ferran Prados, et al.
Brain : a Journal of Neurology|December 14, 2022
Clinical and MRI measures to identify non-acute MOG-antibody disease in adultsRosa Cortese, Marco Battaglini, Ferran Prados, et al.
Pageof 16